Medicamen Biotech Limited

MEDICAMEQ

INE646B01010

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 31/05/2024 pm IST			5-day change	1st Jan Change
500.6 ^INR	+4.18%		-3.45%	-16.90%

31/05	Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	MT
29/05	Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2021

August 13, 2021 at 05:32 pm IST

Medicamen Biotech Limited announced earnings results for the first quarter ended June 30, 2021. For the first quarter, the company announced total revenue was INR 276.09 million compared to INR 278.676 million a year ago. Net income was INR 41.513 million compared to INR 22.441 million a year ago. Basic earnings per share from continuing operations was INR 3.4 compared to INR 1.84 a year ago.

Latest news about Medicamen Biotech Limited

Medicamen Biotech Receives Observations from Greek Regulatory Body; Shares Up 4%	31/05	MT
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	29/05	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08	CI
Medicamen Biotech Limited Recommends Final Dividend for Financial Year 2022-23	29/23/29	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/23/29	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
INDIA STOCKS-Indian shares seen opening higher as global equities attempt bounce	04/22/04	RE
Medicamen Biotech Forays into Domestic Indian Pharmaceutical Business	04/22/04	MT
Medicamen Biotech Forms New Unit	26/22/26	MT
Medicamen Biotech Ties Up with Danish Pharmaceutical Firm for Manufacturing of Drugs	12/22/12	MT
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	25/22/25	CI
Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22	25/22/25	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	08/22/08	CI
Promoter Group Narrows Stake in Medicamen Biotech	04/22/04	MT
Promoter Group Lowers Stake in Medicamen Biotech to 2.93%	10/21/10	MT
Medicamen Biotech's Consolidated Net Profit Climbs in Fiscal Q2	05/21/05	MT
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	03/21/03	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/21/13	CI
Medicamen Biotech Limited Recommends Final Dividend for the Fiscal Year 2021	26/21/26	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	26/21/26	CI
Medicamen Biotech : Shivalik Rasayan Boosts Stake in Medicamen Biotech to 41.79%	24/21/24	MT

Chart Medicamen Biotech Limited

Duration

Period

More charts

Company Profile

Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICAMEN BIOTECH LIMITED	-16.90%	73.34M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	42.02B
OTSUKA HOLDINGS CO., LTD.	+22.40%	21.66B
SANDOZ GROUP AG	+18.48%	15.09B
CIPLA LIMITED	+16.12%	14.21B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.37B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.59B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.56B